<DOC>
	<DOCNO>NCT00396383</DOCNO>
	<brief_summary>This study examine whether 240 µg/kg plerixafor give alone 4 day safe well tolerated multiple myeloma ( MM ) patient . In addition , study determines plerixafor alone use mobilize peripheral blood progenitor cell ( PBPCs ) transplantation MM patient . The minimum number CD34+ cell collect 2*10^6 CD34+ cells/kg target ≧4*10^6 CD34+ cells/kg . Success transplant engraftment measure number day polymorphonuclear leukocyte ( PMN ) platelet ( PLT ) engraftment . Durability transplant assess minimum one year .</brief_summary>
	<brief_title>Treatment With AMD3100 ( Plerixafor ) MM Patients Mobilize PBCs For Collection Transplantation</brief_title>
	<detailed_description>This study examine whether 240 µg/kg plerixafor give alone 4 day safe well tolerated multiple myeloma ( MM ) patient . In addition , study determines 240 µg/kg plerixafor alone use mobilize peripheral blood progenitor cell ( PBPCs ) transplantation MM patient . The minimum number CD34+ cell collect 2*10^6 CD34+ cells/kg target ≧4*10^6 CD34+ cells/kg . Success transplant engraftment measure number day polymorphonuclear leukocyte ( PMN ) platelet ( PLT ) engraftment . Durability engraftment assess minimum one year . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Diagnosis multiple myeloma ( MM ) Eligible autologous transplantation Patients first second partial remission ( PR ) complete remission ( CR ) Patients receive ≦2000 rad prior radiation therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Recovered acute toxic effect prior chemotherapy White blood cell ( WBC ) &gt; 3.0*10^9/l Absolute polymorphonuclear leucocyte ( PMN ) count &gt; 1.5*10^9/l Platelet ( PLT ) count &gt; 150*10^9/l Serum creatinine ≦2.2 mg/dl Serum glutamic oxaloacetic transaminase ( SGOT ) , serum glutamic pyruvic transaminase ( SGPT ) total bilirubin &lt; 2 x upper limit normal ( ULN ) Negative HIV Signed informed consent Patients childbearing potential agree use approve form contraception Patient receive 2 alkylating agent , VBMCP ( combination Vincristine , BCNU ( BisChloronitrosourea ) , Melphalan , Cyclophosphamide , Prednisone ) Patient receive total dose ≧200 mg prior melphalan A comorbid condition , view investigator , render patient high risk treatment complication Patient fail previous collection collection attempt A residual acute medical condition result prior chemotherapy Brain metastases carcinomatous meningitis Acute infection Fever ( temperature &gt; 38 °C / 100.4 °F ) Hypercalcemia ( &gt; 1mg/dl ULN ) Positive pregnancy test female patient Lactating female Patients childbearing potential unwilling implement adequate birth control Patients whose actual body weight exceeds 175 % ideal body weight History ventricular arrhythmia Patient receive thalidomide within 10 day prior receive first dose plerixafor Patients previously receive experimental therapy within 4 week enrol protocol currently enrol another experimental protocol mobilization phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Stem cell mobilization</keyword>
	<keyword>apheresis</keyword>
</DOC>